NovMetaPharma Statistics

Total Valuation

NovMetaPharma has a market cap or net worth of KRW 117.37 billion.

Market Cap	117.37B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

NovMetaPharma has 12.84 million shares outstanding.

Current Share Class	12.84M
Shares Outstanding	12.84M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	25.58%
Owned by Institutions (%)	n/a
Float	9.24M

Valuation Ratios

The trailing PE ratio is 76.17.

PE Ratio	76.17
Forward PE	n/a
PS Ratio	90.60
PB Ratio	22.06
P/TBV Ratio	22.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 32.26

Current Ratio	32.26
Quick Ratio	28.62
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 10.84% and return on invested capital (ROIC) is -2.05%.

Return on Equity (ROE)	10.84%
Return on Assets (ROA)	-1.96%
Return on Invested Capital (ROIC)	-2.05%
Return on Capital Employed (ROCE)	-2.28%
Weighted Average Cost of Capital (WACC)	5.31%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.33
Inventory Turnover	3.01

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +77.03% in the last 52 weeks. The beta is 0.19, so NovMetaPharma's price volatility has been lower than the market average.

Beta (5Y)	0.19
52-Week Price Change	+77.03%
50-Day Moving Average	12,079.20
200-Day Moving Average	12,575.75
Relative Strength Index (RSI)	25.38
Average Volume (20 Days)	5,301

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NovMetaPharma had revenue of KRW 1.30 billion and earned 408.03 million in profits. Earnings per share was 120.00.

Revenue	1.30B
Gross Profit	612.26M
Operating Income	-123.38M
Pretax Income	408.03M
Net Income	408.03M
EBITDA	-75.20M
EBIT	-123.38M
Earnings Per Share (EPS)	120.00

Full Income Statement

Balance Sheet

The company has 3.50 billion in cash and n/a in debt, giving a net cash position of 3.50 billion or 272.22 per share.

Cash & Cash Equivalents	3.50B
Total Debt	n/a
Net Cash	3.50B
Net Cash Per Share	272.22
Equity (Book Value)	5.32B
Book Value Per Share	1,564.89
Working Capital	3.87B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -179.36 million and capital expenditures -84.45 million, giving a free cash flow of -263.81 million.

Operating Cash Flow	-179.36M
Capital Expenditures	-84.45M
Free Cash Flow	-263.81M
FCF Per Share	-20.54

Full Cash Flow Statement

Margins

Gross margin is 47.26%, with operating and profit margins of -9.52% and 31.50%.

Gross Margin	47.26%
Operating Margin	-9.52%
Pretax Margin	31.50%
Profit Margin	31.50%
EBITDA Margin	-5.80%
EBIT Margin	-9.52%
FCF Margin	n/a

Dividends & Yields

NovMetaPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	0.35%
FCF Yield	-0.22%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NovMetaPharma has an Altman Z-Score of 0.95 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.95
Piotroski F-Score	1